Prescription costs and opioid addiction are two of the most significant public health crises in the U.S., but they are often discussed separately. One is about affordability, the other about life-or-death consequences of addiction.
But here’s the truth: they’re two sides of the same broken coin. And ignoring the connection risks losing both battles.
When High Costs Lead to Harm
Across the country, people walk away from the pharmacy counter every day, not because they want to, but because they can’t afford to fill their prescriptions. And when that happens, the consequences aren’t just medical.
Imagine a person in chronic pain from anxiety, depression, or recovering from surgery or injury. They are diagnosed and prescribed something effective, only to leave the pharmacy empty-handed because it costs $1,300 a month. These patients experiencing serious pain may find themselves rationing doses or seeking unregulated options that come with far greater danger.
These aren’t edge cases. They’re common. According to government data, more than 9 million Americans skipped or delayed prescriptions in the last year due to cost.
When legal access breaks down, the illegal market steps in. The opioid crisis didn’t start in the streets. It started in the clinic with brand-name drugs that were overprescribed, under-regulated, and wildly profitable. The crisis deepened when those same drugs became unaffordable, restricted, or stigmatized, causing patients to delay treatment, split pills, or turn to risky alternatives, including street opioids and counterfeit drugs. This isn’t just about economics, it’s about survival.
That’s the overlap. Unaffordable care isn’t just a barrier — it’s a trigger.
Big Pharma: Profit to Crisis to Cure (and Profit Again)
The opioid epidemic began with the overprescription of legal drugs like OxyContin. Now, many of the same companies that profited from that crisis are selling expensive addiction treatments. They monetized both the problem and the solution.
Meanwhile, new FDA leadership may loosen oversight of drug approval and pricing, which is raising concerns about prioritizing speed and market value over safety and access.
Policy Whiplash: Help on One Front, Cuts on the Other
While the current administration pushes for “most-favored-nation pricing” to lower U.S. drug costs, Congress is simultaneously considering rollbacks to Medicaid, the largest funder of opioid addiction treatment in the country.
Here’s the paradox: Medicaid treats more than 1.8 million Americans with opioid use disorder, thanks largely to the Affordable Care Act’s expansion. Cutting that support, particularly in states like West Virginia and Louisiana, would mean dismantling the very infrastructure built to fight addiction.
As Bloomberg columnist Ron Brownstein recently put it, that’s “unilateral disarmament” in the war against opioid addiction.
Access is the Common Thread
Whether the challenge is chronic illness or opioid recovery, the system fails when patients can’t afford the medications they need. That’s why the fight against high drug prices and the fight against addiction aren’t separate, they’re interdependent.
We cannot win one while undermining the other.
RazorMetrics: A Smarter Front Line
At RazorMetrics, we support prescribers with clinically sound, cost-saving options that help patients stay adherent, avoid financial harm, and reduce risk of misuse or substitution. We don’t wait for policy change. We equip providers with tools that reduce cost and complexity right now.
Because when patients can’t afford their medications, it’s not just a missed dose — it’s a potential relapse, a hospital visit, or a preventable tragedy.
Two crises. One solution. Start by making treatment affordable. RazorMetrics is here to help providers do exactly that.
